All In Biotech

Drug Trial Radar · NCT03036098

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,314 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,314

Actual

Start

Mar 24, 2017

Primary completion

Aug 30, 2024

Study completion Oct 20, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Jan 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.

Conditions

  • Urothelial Cancer

Interventions

  • NivolumabBiological

    Specified Dose on Specified Days

  • IpilimumabBiological

    Specified Dose on Specified Days

  • GemcitabineDrug

    Specified Dose on Specified Days

  • CisplatinDrug

    Specified Dose on Specified Days

  • CarboplatinDrug

    Specified Dose on Specified Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary StudyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
  2. Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary StudyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
  3. Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-studyTime frame: From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)
  4. Overall Survival (OS) in Cisplatin-eligible Participants for Sub-studyTime frame: From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)

Locations

174 sites in 30 countries. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Anchorage, Alaska

  • Local Institution - 0115

    Fresno, California

  • St Joseph Heritage Healthcare

    Santa Rosa, California

  • Local Institution - 0051

    Boca Raton, Florida

  • Local Institution - 0087

    Fort Lauderdale, Florida

  • Local Institution - 0062

    Jacksonville, Florida

  • Local Institution - 0004

    Athens, Georgia

  • Local Institution - 0033

    Thomasville, Georgia

  • Local Institution - 0046

    Chicago, Illinois

  • Local Institution - 0117

    New Orleans, Louisiana

  • Local Institution - 0056

    Boston, Massachusetts

  • Local Institution - 0073

    Boston, Massachusetts

  • Local Institution - 0208

    Boston, Massachusetts

  • Local Institution - 0207

    Milford, Massachusetts

  • Local Institution - 0063

    Ann Arbor, Michigan

  • Local Institution - 0002

    Burnsville, Minnesota

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Local Institution - 0032

    Kansas City, Missouri

  • Local Institution - 0095

    St Louis, Missouri

  • Local Institution - 0057

    Manchester, New Hampshire

  • Local Institution - 0084

    Albuquerque, New Mexico

  • Local Institution - 0083

    Buffalo, New York

  • Local Institution - 0014

    Mineola, New York

  • Local Institution - 0072

    New York, New York

  • Local Institution - 0116

    Durham, North Carolina

  • Local Institution - 0082

    Columbus, Ohio

  • Local Institution - 0104

    Portland, Oregon

  • Local Institution - 0013

    Pittsburgh, Pennsylvania

  • Local Institution - 0086

    Kirkland, Washington

  • Local Institution - 0009

    Buenos Aires, Argentina

  • Local Institution - 0134

    Córdoba, Argentina

  • Local Institution - 0006

    Córdoba, Argentina

  • Local Institution - 0008

    Viedma, Argentina

  • Local Institution - 0005

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0007

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0096

    Waratah, New South Wales, Australia

  • Local Institution - 0099

    Westmead, New South Wales, Australia

  • Local Institution - 0188

    South Brisbane, Queensland, Australia

  • Local Institution - 0120

    Tugun, Queensland, Australia

  • Local Institution - 0101

    Heidelberg, Victoria, Australia

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.